Which therapeutic areas do these alliances target?

The alliances target obesity, oncology, and neurodegeneration.

Will these alliances affect Eli Lilly's stock?

No immediate impact was reported, but they could strengthen the pipeline long-term.

Eli Lilly Enters New R&D Alliances with Biotechs Abbisko and BioArctic

Eli Lilly has entered into two new research and license agreements with Abbisko Therapeutics and BioArctic, with total milestone payments up to $2.67 billion, to broaden its pipeline across multiple therapeutic areas.

June 25, 2026

1 min read

Source: Simply Wall St.

Key Numbers

abbisko milestones

1.90B

bioarctic milestones

770M

Eli Lilly (NYSE: LLY) announced two new research and license agreements with biotech firms Abbisko Therapeutics and BioArctic, aiming to expand its therapeutic pipeline in obesity, oncology, and neurodegeneration.

Deal Details

Abbisko Therapeutics: The multi-target discovery deal includes up to $1.90 billion in milestone payments plus royalties on future product sales.
BioArctic: The agreement includes potential milestone payments of up to $770 million, with similar royalty terms.

Strategic Context

These alliances are part of Eli Lilly's strategy to bolster external innovation alongside its internal programs. The partnerships highlight how the company is leveraging external collaborations to broaden its pipeline beyond internal efforts.

What This Means for Investors

These deals represent a potentially positive step for Eli Lilly's pipeline expansion, but success depends on future research outcomes and regulatory approvals. Investors should monitor the progress of these programs.

Frequently Asked Questions

The potential milestone payments are up to $1.90 billion for Abbisko and $770 million for BioArctic, totaling $2.67 billion.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.